嵌合抗原受体
免疫原性
免疫疗法
医学
免疫系统
癌症免疫疗法
临床试验
癌症
免疫学
抗原
免疫检查点
癌症治疗
内科学
作者
Lien Lybaert,Kris Thielemans,Steven A. Feldman,Sjoerd H. van der Burg,Cedric Bogaert,Patrick A. Ott
标识
DOI:10.1016/j.trecan.2023.02.004
摘要
In the past decade, immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cell therapy have brought immunotherapy to the forefront of cancer treatment; however, only subsets of patients benefit from current approaches. Neoantigen-driven therapeutics specifically redirect the immune system of the patient to enable or reinduce its ability to recognize and eliminate cancer cells. The tumor specificity of this strategy spares healthy and normal cells from being attacked. Consistent with this concept, initial clinical trials have demonstrated the feasibility, safety, and immunogenicity of neoantigen-directed personalized vaccines. We review neoantigen-driven therapy strategies as well as their promise and clinical successes to date.
科研通智能强力驱动
Strongly Powered by AbleSci AI